Immune checkpoint inhibitors can cause immune-related adverse events when they are used in tumor immunotherapy,but the cases of diabetes mellitus are rare.This article reported a case of diabetes mellitus complicated with ketoacidosis caused by the treatment of lung cancer patients with immune checkpoint inhibitor Sindilimab and related literature review.
维普
万方数据